Suppr超能文献

基于枯草芽孢杆菌的新型 UDP-糖基转移酶,通过代谢工程酵母生产具有生物活性的非天然人参皂苷。

Production of a bioactive unnatural ginsenoside by metabolically engineered yeasts based on a new UDP-glycosyltransferase from Bacillus subtilis.

机构信息

State Key Laboratory of Bioactive Substance and Function of Natural Medicines & Key Laboratory of Biosynthesis of Natural Products of National Health and Family Planning Commission, Institute of Materia Medica, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing 100050, China.

State Key Laboratory of Bioactive Substance and Function of Natural Medicines & Key Laboratory of Biosynthesis of Natural Products of National Health and Family Planning Commission, Institute of Materia Medica, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing 100050, China.

出版信息

Metab Eng. 2017 Nov;44:60-69. doi: 10.1016/j.ymben.2017.07.008. Epub 2017 Aug 2.

Abstract

Ginsenosides are the main bioactive constituents of Panax species, which are biosynthesized by glycosylation at C3-OH and/or C20-OH of protopanaxadiol (PPD), C6-OH and/or C20-OH of protopanaxatriol (PPT). The C12-glycosylated ginsenosides have scarcely been identified from Panax species. The C12-glycosylated ginsenosides produced from PPD by chemical semi-synthesis have been reported to exhibit higher cytotoxicity than the natural ginsenosides. However, the chemical semi-synthesis approach is not practical due to its complexity and high cost. In our study, a new UDP-glycosyltransferase UGT109A1 was identified from Bacillus subtilis. This enzyme transferred a glucose moiety to C3-OH and C20-OH of dammarenediol-II (DM), C3-OH and C12-OH of PPD and PPT respectively to produce the unnatural ginsenosides 3β-O-Glc-DM, 3β,20S-Di-O-Glc-DM, 3β,12β-Di-O-Glc-PPD and 3β,12β-Di-O-Glc-PPT. Among these unnatural ginsenosides, 3β,12β-Di-O-Glc-PPT is a new compound which has never been reported before. The anti-cancer activities of these unnatural ginsenosides were evaluated in vitro and in vivo. 3β,12β-Di-O-Glc-PPD exhibited higher anti-lung cancer activity than Rg3, which is the most active natural ginsenoside against lung cancer. Finally, we constructed metabolically engineered yeasts to produce 3β,12β-Di-O-Glc-PPD by introducing the genes encoding B. subtilis UGT109A1, Panax ginseng dammarenediol-II synthase (DS), P. ginseng cytochrome P450-type protopanaxadiol synthase (PPDS) together with Arabidopsis thaliana NADPH-cytochrome P450 reductase (ATR1) into Saccharomyces cerevisiae INVSc1. The yield of 3β,12β-Di-O-Glc-PPD was increased from 6.17mg/L to 9.05mg/L by overexpressing tHMG1. Thus, this study has established an alternative route to produce the unnatural ginsenoside 3β,12β-Di-O-Glc-PPD by synthetic biology strategies, which provides a promising candidate for anti-cancer drug discovery.

摘要

人参皂苷是人参属植物的主要生物活性成分,通过在原二醇的 C3-OH 和/或 C20-OH、原三醇的 C6-OH 和/或 C20-OH 上进行糖基化生物合成。从人参属植物中很少鉴定出 C12-糖基化的人参皂苷。据报道,通过化学半合成从达玛烷二醇 II(DM)产生的 C12-糖基化人参皂苷比天然人参皂苷具有更高的细胞毒性。然而,由于其复杂性和高成本,化学半合成方法并不实用。在我们的研究中,从枯草芽孢杆菌中鉴定出一种新的 UDP-糖基转移酶 UGT109A1。该酶将一个葡萄糖基分别转移到 DM 的 C3-OH 和 C20-OH、PPD 和 PPT 的 C3-OH 和 C12-OH 上,生成非天然的人参皂苷 3β-O-Glc-DM、3β,20S-二-O-Glc-DM、3β,12β-二-O-Glc-PPD 和 3β,12β-二-O-Glc-PPT。在这些非天然人参皂苷中,3β,12β-二-O-Glc-PPT 是一种以前从未报道过的新化合物。这些非天然人参皂苷的体外和体内抗癌活性进行了评估。3β,12β-二-O-Glc-PPD 对肺癌的抗癌活性高于 Rg3,Rg3 是对肺癌最有效的天然人参皂苷。最后,我们通过引入编码枯草芽孢杆菌 UGT109A1、人参达玛烷二醇 II 合酶(DS)、人参细胞色素 P450 型原二醇合酶(PPDS)以及拟南芥 NADPH-细胞色素 P450 还原酶(ATR1)的基因,构建了代谢工程酵母,通过在酿酒酵母 INVSc1 中过表达 tHMG1,将 3β,12β-二-O-Glc-PPD 的产量从 6.17mg/L 提高到 9.05mg/L。因此,本研究通过合成生物学策略建立了生产非天然人参皂苷 3β,12β-二-O-Glc-PPD 的替代途径,为抗癌药物发现提供了有前途的候选药物。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验